Conference Registration, Materials Pick-Up and Continental Breakfast in the Exhibit Hall

Coffee Break and Networking

Networking Lunch, Discussions with Exhibitors and View Posters

Standard Tools for Biology
Danny Cabrera, CEO, Biobots Inc, United States of America

Biology is the most sophisticated manufacturing technology that we know of. If we could control life, we could cure disease, eliminate the organ waiting list, revert climate change and push life to other planets. However, our ability to engineer living systems has been restricted by the lack of standard tools that exist for manipulating biology. BioBots is addressing this need by creating a standard suite of digital biofabrication tools. Together with our partners and clients, we are blending biology with robotics and software to reimagine the modern laboratory and push the human race forward.

3D Bioprinting with Stem Cells for Soft Tissue Engineering
Paul Gatenholm, Professor, Director of 3D Bioprinting Center, Chalmers University of Technology, Sweden; CEO, CELLHEAL AS, Norway, Sweden
Erik Gatenholm, Director Of Operations, Cellink By Aptab, Sweden

The introduction of 3D bioprinting is expected to revolutionize the field of tissue engineering and regenerative medicine, which enables the reconstruction of living tissue and organs using the patient’s own cells. We have developed novel bioinks based on polysaccharide nanofibrils with unique combination of printing fidelity good mechanical properties and biocompatibility. Nanofibril dispersion have extremely shear thinning properties and high zero shear viscosity. 3D bioprinting fidelity which is achieved with these bioinks made it possible to print complex cartilage tissue shapes such as ear, nose and meniscus.

Print-to-Screen: A High-Throughput Multiplexed Microfluidic Analytical Platform
Tingrui Pan, Professor, Department of Biomedical Engineering, University of California-Davis, United States of America

Coffee Break and Networking in the Exhibit Hall

Bioinks Supporting Angiogenic Potential in Organ Printing
William G Whitford, Life Science Strategic Solutions Leader, DPS Group, United States of America
Michael Golway, President & CEO, Advanced Solutions, Inc., United States of America

Larger tissues require cells capable of angiogenesis. Bioinks and proto-organ progression media must support these cell types requiring their own optimal growth/differentiation factors and metabolites.

The Total Quality Approach for Cytocentric Biofabrication
Alicia Henn, Chief Scientific Officer, BioSpherix, Ltd., United States of America

The ideal environment for a biofabrication apparatus is one that provides a full-time physical barrier between the apparatus and room air. The use of a barrier isolator to surround a bioprinter not only lowers biosafety risks for personnel, but also allows containment of a continuously sterile, controlled atmosphere for materials, cells, and the completed organ. We will actively discuss the many ways that a total quality approach to the biofabrication environment can bring reproducible control to production processes from materials preparation through organ manufacture to batch records.

Networking Cocktail Reception for All Delegates, Speakers, Sponsors and Exhibitors on the 15th Floor with a View of Boston and the Charles River

Close of Day 1 of the Conference. Microfluidics in Bioprinting Dinner Training Course Begins.

Morning Coffee, Breakfast Pastries, and Networking

Hybrid Crosslink Hydrogels with Controlled Cell Adhesion for 3D-Bioprinted Wound and Deep Burn Implantable Constructs
Josef Jancár, Director Institute of Materials Chemistry, Faculty of Chemistry and Program Coordinator Advanced Materials, Central European Institute of Technology, Brno University of Technology, Czech Republic, Czech Republic

Amphiphilic BCPs have attracted a great deal of attention in terms of their ability to form micelles, nanocapsules, nanospheres, core-shell nanoparticles in the size of 10–100 nm, characterized by a core-shell architecture in which the core serves as a reservoir for the incorporation of poorly water soluble drugs; while, the hydrophilic shell provides a protective interface between the core and the external medium. Active substance release can be manipulated by choosing biodegradable polymers with different surface or bulk erosion rates, and external conditions such as pH and temperature changes may function as a switch to trigger drug release. Hierarchical structure can be formed simulating layered skin structure employing various techniques including 3D bioprinting. The modification with itaconic anhydride (ITA) that brings carboxylic functional groups and double bonds to the end of light, temperature and pH sensitive gel forming macromonomers has attracted attention since they can be cross-linked either covalent bonding via rapid photopolymerization and/or physically by hydrogen bond or ionic interactions of carboxylic groups with Ca²⁺ in order to produce new functionalized 3D-hydrogel network.

4D Bioprinting: Programming Self-Organization to Engineer Biological Tissues
Fabien Guillemot, Chief Executive Officer, Poietis, France

Bioprinting has been defined as “the use of computer-aided transfer processes for patterning and assembling living and non-living materials with a prescribed 2D or 3D organization in order to produce bio-engineered structures serving in regenerative medicine, pharmacokinetic and basic cell biology studies”. From a technological point of view, the Laser-Assisted Bioprinting (LAB) technology has emerged as an alternative method to inkjet and bioextrusion methods, thereby overcoming some of their limitations (namely clogging of print heads or capillaries) to pattern living cells and biomaterials with a micron-scale resolution and high cell viability. By harnessing this high cell printing resolution, we observe that tissue self-organization depends on the cell patterns initially printed by LAB, as well as cell types. We introduce from experiments performed in vitro and in vivo the 4D Bioprinting paradigm.

3D Bioprinting of Cells-Loaded ECM Biomimetic Hydrogels for Tissue Formation
Wojciech Swieszkowski, Professor in Materials Design Division, Faculty of Materials Science and Engineering, Warsaw University of Technology, Poland

The aim of the study is to demonstrate how to print 3D  biomimetic  hydrogel  scaffolds  for tissue engineering  with  high  cell  density,  high  cell  viability  and  high  printing resolution  using a novel 3D bioprinting approach. We used an innovative 3D deposition system based on a coaxial-needles extruder developed in-house. The bioinks were composed of modified biopolymers like gelatin, alginate, hyaluronic acid or chitosan. The biomimetic hydrogel were loaded with different types of cell including bone marrow-derived human mesenchymal stem cells or chondrocytes. Our findings show that the presented 3D printing method is highly robust and accurate and allows for formation of 3D biostructures which after some period develop into neo-tissues.

Coffee Break and Networking in the Exhibit Hall

The Intellectual Property Landscape of 3D Printing in the Life Sciences
Robert Esmond, Director, Sterne, Kessler, Goldstein & Fox P.L.L.C, United States of America
Jennifer Bush, General Counsel, Organovo, Inc., United States of America

This presentation will focus on the patent landscape covering 3D printing in the life sciences.  In addition, the presentation will discuss limitations on recent trends regarding patent eligibility under 35 U.S.C. § 101, as well as the application of 35 USC § 271(e) research exemption to patent infringement in the context of bioprinted research tools.

Networking Lunch, Discussions with Exhibitors and View Posters

Breaking Down the Bioprinting Value Chain to Find Successful Business Models
Anthony Vicari, Analyst, Advanced Materials, Lux Research, Inc., United States of America

Coffee and Panel Discussion: Challenges for the Implementation of Tissue Engineering and Bioprinting in Clinical Practice -- Issues and Perspectives

Close of Conference